CIALIS Drug Patent Profile

Which patents cover Cialis, and what generic alternatives are available?

Cialis is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in CIALIS is tadalafil. There are twenty-five drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the tadalafil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cialis

A generic version of CIALIS was approved as tadalafil by TEVA PHARMS USA on May 22^nd, 2018.

Summary for CIALIS

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CIALIS

Paragraph IV (Patent) Challenges for CIALIS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CIALIS	Tablets	tadalafil	2.5 mg	021368	1	2008-10-14
CIALIS	Tablets	tadalafil	5 mg, 10 mg and 20 mg	021368	1	2007-11-21

US Patents and Regulatory Information for CIALIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-004	Jan 7, 2008		DISCN	Yes	No
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-003	Nov 21, 2003	AB1	RX	Yes	Yes
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-001	Nov 21, 2003	AB1	RX	Yes	No
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-002	Nov 21, 2003	AB1	RX	Yes	No

International Patents for CIALIS

See the table below for patents covering CIALIS around the world.

Country	Patent Number	Title	Estimated Expiration
China	1195290
Eurasian Patent Organization	004872	β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ (beta-CARBOLINE PHARMACEUTICAL COMPOSITIONS)
Luxembourg	91017
Taiwan	378210
World Intellectual Property Organization (WIPO)	0108686
South Korea	100577057
European Patent Office	0740668	DERIVES TETRACYCLIQUES, LEURS PROCEDES DE PREPARATION ET LEUR UTILISATION (TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE)

Supplementary Protection Certificates for CIALIS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0740668	PA2003001	Lithuania		PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328
2059246	C02059246/01	Switzerland		PRODUCT NAME: MACITENTAN UND TADALAFIL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 69446 10.10.2024
2059246	C202430051	Spain		PRODUCT NAME: UNA COMBINACION DE (A) MACITENTAN O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO Y (B) TADALAFILO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/24/1859; DATE OF AUTHORISATION: 20240927; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/24/1859; DATE OF FIRST AUTHORISATION IN EEA: 20240927
0740668	03C0017	France		PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112
2101777	CA 2016 00024	Denmark		PRODUCT NAME: AMBRISENTAN USED IN COMBINATION TREATMENT WITH TADALAFIL; REG. NO/DATE: EU/1/08/451 (001-004) 20151125
2101777	93081	Luxembourg		PRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125
0740668	91017	Luxembourg

CIALIS Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is the Investment Outlook for CIALIS?

CIALIS (tadalafil), developed by Eli Lilly and commercialized in partnership with other firms, is a leading phosphodiesterase type 5 (PDE5) inhibitor primarily indicated for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH). Its long half-life and dual indications differentiate it from competitors. The drug commands sustained market interest but faces patent expiration risks and competitive pressures.

What Are the Key Market Dynamics?

Market Size and Growth

• Global ED drug market value estimated at $4.2 billion in 2022[1].
• Compound annual growth rate (CAGR) expected at 5% from 2023 to 2030[2].
• CIALIS controls approximately 20-25% of this segment, with regional variations favoring North America and Europe.

Competitive Landscape

• Main competitors include Viagra (sildenafil), Levitra (vardenafil), and newer treatments like avanafil.
• CIALIS’s unique attributes include a longer duration of action (up to 36 hours) and BPH indications, which offer differentiation.
• Patent in the U.S. expired in 2018, with key generic entrants entering the market.

Patent and Regulatory Status

• Primary patent protection expired in the U.S. in 2018.
• Supplementary patents on formulation and methods extend exclusivity in some regions until 2025.
• Patent cliffs risk significant revenue erosion, especially in North America.
• Regulatory approvals extend to several markets; ongoing filings for new indications could diversify revenue streams.

Sales and Revenue Trends

• 2022 global sales: approximately $1.4 billion, with North American sales at around $650 million.
• Revenue decline observed post-2018 patent expiry, with strategic launches of biosimilars and generics impacting market share.
• Eli Lilly continues to pursue new formulations and combinations to sustain sales.

What Are the Investment Fundamentals?

Revenue and Profitability

Metric	2021	2022 (est.)	Notes
Global Sales	$1.55B	$1.4B	Slight decline, impacted by generics
Gross Margin	~70%	~68%	Slight compression after patent expiry
Operating Margin	~40%	~35%	Margin compression related to increased competition

R&D Pipeline and Growth Potential

• Eli Lilly continues research into new formulations and delivery systems.
• Development of combination therapies and niche indications (e.g., pulmonary hypertension) could expand revenue.
• Focus on male health and BPH may provide diversification.

Regulatory and Legal Risks

• Patent expiry exposes CIALIS to generics, reducing prices and market share.
• Patent challenges and legal disputes could delay new launches.
• Regulatory hurdles in emerging markets may restrict access or delay commercialization.

Strategic Initiatives and Market Penetration

• Emphasis on expanding in Asian markets with localized formulations.
• Marketing strategies targeting aging populations and comorbidities.
• Attempts to extend patent protection via new formulations and delivery methods.

Financial Outlook and Valuation

• Market analysts estimate a compound annual revenue decline of 3-5% in the next five years due to patent expiries.
• Long-term value hinges on pipeline success and market share retention.
• Eli Lilly’s diversified portfolio lessens reliance solely on CIALIS; expected to buffer overall earnings.

What Are the Risks and Opportunities?

Risks

• Patent expiration risks leading to generic substitution.
• Competitive pressure from lower-cost generics.
• Regulatory delays or restrictions in key markets.
• Market saturation in developed economies.

Opportunities

• Patent extensions and new formulations delaying generics.
• Expansion into new indications like pulmonary hypertension.
• Rising global demand for male health and aging demographic trends.
• Strategic partnerships for biosimilars and generics.

What Are the Valuation Benchmarks?

• The current enterprise value (EV) of Eli Lilly reflects robust diversification but considers patent risks.
• CIALIS-specific valuation depends heavily on market share retention post-patent expiry.
• Comparable PDE5 inhibitors, like sildenafil and vardenafil, traded at discounted multiples post-patent expiration, with some premium for ongoing niche uses.

Key Takeaways

• CIALIS remains a significant revenue contributor for Eli Lilly but faces patent expiration and generic competition.
• Growth opportunities include new formulations, indications, and geographic expansion.
• Margins are under pressure but remain healthy relative to the industry.
• Long-term investment depends on Eli Lilly’s pipeline success and ability to defend market share.
• Risks primarily stem from patent challenges and competitive pricing pressures.

FAQs

1. How does CIALIS compare to other ED treatments?
CIALIS’s longer duration (up to 36 hours) offers an advantage over sildenafil and vardenafil, which last 4-6 hours. Its BPH indication broadens its utility.

2. What is the impact of patent expiry on CIALIS’s sales?
Patent expiry in the U.S. in 2018 led to increased generic competition, causing revenues to decline by approximately 10-20% in subsequent years.

3. Can Eli Lilly extend CIALIS’s patent protection?
Yes, through formulations, delivery systems, or new indications, which could delay generic entry.

4. What are the prospects for CIALIS in emerging markets?
Growing healthcare infrastructure and aging populations support expansion, though regulatory and pricing challenges remain.

5. What are the main growth drivers for CIALIS beyond revenue stabilization?
New formulations, combination therapies, and expansion into additional indications like pulmonary hypertension.

---

References

[1] MarketWatch, “Global Erectile Dysfunction Market,” 2022.
[2] Grand View Research, “Erectile Dysfunction Drugs Market Size, Share & Trends,” 2023.